ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

  1. 学術雑誌論文
  2. 各雑誌掲載論文
  1. 学術雑誌論文
  2. 浜松医科大学優秀論文賞

Olanzapine Plus Triple Antiemetic Therapy for the Prevention of Carboplatin-Induced Nausea and Vomiting: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial

http://hdl.handle.net/10271/0002000383
http://hdl.handle.net/10271/0002000383
496dec23-ac60-4b91-8076-cc5950d3d104
名前 / ファイル ライセンス アクション
最優秀_JCO-42-2780.pdf JCO-42-2780.pdf (977 KB)
license.icon
Item type 学術雑誌論文 / Journal Article(1)
公開日 2025-04-15
タイトル
タイトル Olanzapine Plus Triple Antiemetic Therapy for the Prevention of Carboplatin-Induced Nausea and Vomiting: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial
言語 en
言語
言語 eng
資源タイプ
資源タイプ識別子 http://purl.org/coar/resource_type/c_6501
資源タイプ journal article
アクセス権
アクセス権 open access
アクセス権URI http://purl.org/coar/access_right/c_abf2
著者 Inui, Naoki

× Inui, Naoki

en Inui, Naoki
Hamamatsu University School of Medicine..et al.

ja ISNI 浜松医科大学 他 0000000089376696

ja-Kana ハママツイカダイガク ホカ

Search repository
Suzuki, Takahito

× Suzuki, Takahito

en Suzuki, Takahito

Search repository
Tanaka, Kazuki

× Tanaka, Kazuki

en Tanaka, Kazuki

Search repository
Karayama, Masato

× Karayama, Masato

en Karayama, Masato

Search repository
Inoue, Yusuke

× Inoue, Yusuke

en Inoue, Yusuke

Search repository
Mori, Kazutaka

× Mori, Kazutaka

en Mori, Kazutaka

Search repository
Yasui, Hideki

× Yasui, Hideki

en Yasui, Hideki

Search repository
Hozumi, Hironao

× Hozumi, Hironao

en Hozumi, Hironao

Search repository
Suzuki, Yuzo

× Suzuki, Yuzo

en Suzuki, Yuzo

Search repository
Furuhashi, Kazuki

× Furuhashi, Kazuki

en Furuhashi, Kazuki

Search repository
Fujisawa, Tomoyuki

× Fujisawa, Tomoyuki

en Fujisawa, Tomoyuki

Search repository
Matsuura, Shun

× Matsuura, Shun

en Matsuura, Shun

Search repository
Nishimoto, Koji

× Nishimoto, Koji

en Nishimoto, Koji

Search repository
Matsui, Takashi

× Matsui, Takashi

en Matsui, Takashi

Search repository
Asada, Kazuhiro

× Asada, Kazuhiro

en Asada, Kazuhiro

Search repository
Hashimoto, Dai

× Hashimoto, Dai

en Hashimoto, Dai

Search repository
Fujii, Masato

× Fujii, Masato

en Fujii, Masato

Search repository
Niwa, Mitsuru

× Niwa, Mitsuru

en Niwa, Mitsuru

Search repository
Uehara, Masahiro

× Uehara, Masahiro

en Uehara, Masahiro

Search repository
Matsuda, Hiroyuki

× Matsuda, Hiroyuki

en Matsuda, Hiroyuki

Search repository
Koda, Keigo

× Koda, Keigo

en Koda, Keigo

Search repository
Ikeda, Masaki

× Ikeda, Masaki

en Ikeda, Masaki

Search repository
Inami, Nao

× Inami, Nao

en Inami, Nao

Search repository
Tamiya, Yutaro

× Tamiya, Yutaro

en Tamiya, Yutaro

Search repository
Kato, Masato

× Kato, Masato

en Kato, Masato

Search repository
Nakano, Hideki

× Nakano, Hideki

en Nakano, Hideki

Search repository
Mino, Yasuaki

× Mino, Yasuaki

en Mino, Yasuaki

Search repository
Enomoto, Noriyuki

× Enomoto, Noriyuki

en Enomoto, Noriyuki

Search repository
Suda, Takafumi

× Suda, Takafumi

en Suda, Takafumi

Search repository
書誌情報 en : Journal of Clinical Oncology

巻 42, 号 23, p. 2780-2789, 発行日 2024-06-04
出版者
出版者 Wolters Kluwer Health
言語 en
権利
権利情報 (C) 2024 by American Society of Clinical Oncology. Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: http://creativecommons.org/licenses/by-nc-nd/4.0/
抄録
内容記述タイプ Abstract
内容記述 PURPOSE
We evaluated the efficacy and safety of antiemetic therapy with olanzapine, a neurokinin-1 receptor antagonist (RA), a 5-hydroxytryptamine-3 (5-HT3) RA, and dexamethasone for preventing chemotherapy-induced nausea and vomiting in patients receiving carboplatin-containing chemotherapy.
PATIENTS AND METHODS
Chemotherapy-naïve patients scheduled to receive carboplatin (AUC ≥5) were randomly assigned to receive either olanzapine 5 mg once daily (olanzapine group) or placebo (placebo group) in combination with aprepitant, a 5-HT3 RA, and dexamethasone. The primary end point was the complete response (CR; no vomiting and no rescue therapy) rate in the overall phase (0-120 hours). Secondary end points included the proportion of patients free of nausea and safety.
RESULTS
In total, 355 patients (78.6% male, median age 72 years, 100% thoracic cancer), including 175 and 180 patients in the olanzapine and placebo groups, respectively, were evaluated. The overall CR rate was 86.9% in the olanzapine group versus 80.6% in the placebo group. The intergroup difference in the overall CR rate was 6.3% (95% CI, ―1.3 to 13.9). The proportions of patients free of chemotherapyinduced nausea in the overall (88.6% in the olanzapine group v 75.0% in the placebo group) and delayed (89.7% v 75.6%, respectively) phases were significantly higher in the olanzapine group than in the placebo group (both P< .001). Somnolence was observed in 43 (24.6%) and 41 (22.9%) patients in the olanzapine and placebo groups, respectively, and no events were grade ≥3 in severity.
CONCLUSION
The addition of olanzapine was not associated with a significant increase in the overall CR rate. Regarding the prevention of nausea, adding olanzapine provided better control in patients receiving carboplatin-containing chemotherapy, which needs further exploration.
注記
内容記述 令和6年 浜松医科大学優秀論文賞:最優秀論文賞
受賞者:乾 直輝
ISSN
収録物識別子タイプ PISSN
収録物識別子 0732-183X
EISSN
収録物識別子タイプ EISSN
収録物識別子 1527-7755
NII書誌ID
収録物識別子タイプ NCID
収録物識別子 AA10638385
PubMed番号
関連タイプ isIdenticalTo
識別子タイプ PMID
関連識別子 38833659
出版社DOI
関連タイプ isIdenticalTo
識別子タイプ DOI
関連識別子 https://doi.org/10.1200/JCO.24.00278
著者版フラグ
出版タイプ VoR
出版タイプResource http://purl.org/coar/version/c_970fb48d4fbd8a85
戻る
0
views
See details
Views

Versions

Ver.1 2025-04-11 06:04:14.652760
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR 2.0
  • OAI-PMH JPCOAR 1.0
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by WEKO3


Powered by WEKO3